Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-13
2006-06-13
Low, Christopher S. F. (Department: 1614)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C424S450000
Reexamination Certificate
active
07060828
ABSTRACT:
This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.
REFERENCES:
patent: 5023087 (1991-06-01), Yau-Young
patent: 5552156 (1996-09-01), Burke
patent: 5837282 (1998-11-01), Fenske et al.
patent: 6355268 (2002-03-01), Slater et al.
patent: WO 95/08986 (1995-04-01), None
patent: WO 98/17256 (1998-04-01), None
patent: WO 99/13816 (1999-03-01), None
patent: WO 99/13816 (1999-03-01), None
patent: WO 99/51202 (1999-10-01), None
patent: WO 00/23052 (2000-04-01), None
Burris III, et al.,J. Natl. Cancer Inst., 84:1816-1820 (1992).
Clements, et al.,Cancer Chemotherm. Pharmacol., 44:411-416 (1999).
Emerson, et al.,Cancer Res., 55:603-609 (1995).
Erickson-Miller, et al..,Cancer Chemother. Pharmacol., 39:467-472 (1997).
Grochow, et al.,Drug. Metab. Dispos., 20(5):706-713 (1992).
Hardman, et al.,Anticancer Res., 19:2269-2274 (1999).
Hsiang, et al.,Cancer Res., 48:1722-1726 (1988).
Madden, et al.,Chem. Phys. Lipids, 53:37-46 (1990).
Madden, et al., “Encapsulation of Topotecan in lipid-based carrier systems. Evaluation of drug stability and plasma elimination in a murine model, and comparison of antitumor efficacy against murine L1210 and B16 tumors,”Proc. of ASCO, 17:abstract754 (1998).
Mayer, et al.,Biochim. Biophys. Acta, 1025:143-151 (1990).
McCabe, et al.,Cancer Invest., 12(3):308-313 (1994).
O'Leary, et al.,Clin. Cancer Res., 5:181-187 (1999).
Ormrod, et al.,Drugs, 58(3)533-551 (1999).
Tardi, et al.,Cancer Res., 60:3389-3393 (2000).
Thompson,Biochim. Biophys. Acta, 1400:301-319 (1998).
Wall, et al.,J. Am. Chem. Soc., 88:3888-3890 (1966).
Abraham, S.A., K. Edwards, et al. “An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes,”J Control Release 96(3): 449-61, 2004.
Apostolidou, E., G. Garcia-Manero, et al. “Phase I Study of OSI-211, a Novel Liposomal Topoisomerase 1 (Topo 1) Inhibitor, in Patients withs Refractory Leukemia,”Blood, 2002. Abstract #4575.
Biloti, D. N., A. Santana Maria Helena, et al. “Lipid membrane with low proton permeability,”Biochim Biophy Acta 1611(1-2): 1-4, 2003.
Bom, D., D. P. Curran, et al. “The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity,”J Med Chem 43(21): 3970-80, 2000.
Bom, D., D. P. Curran, et al. “the highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity,”J Control Release 74(1-3): 325-33, 2001.
Burke, T. G. and D. Bom, “Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo,”Ann N Y Acad Sci 922: 36-45, 2000.
Burke, T. G. and X. Gao “Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine,”J Pharm Sci 83(7): 967-9, Jul. 1994.
Burke, T. G., E. Staubus Alfred, et al. “Liposomal stabilization of Camptothecin lactone ring.”J Am Chem Soc 114:8318-8319, 1992.
Burke, T. G., Z. Mi, et al. “Liposomal stabilization of camptothecins,”Proc Amer Assoc Cancer Res. 35:416, Mar. 1994. Abstract #2479.
Chou, T.-H., S.-C. Chen, et al. “Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method.”Journal of Bioscience and Bioengineering. 95(4):405-408, 2003.
Chow, D. S. L., G. Chen, et al. “Liposomal camptothecin and 9-nitro-camptothecin: Formulation, pharmacokinetics and preclinical anti-tumor activity.”Proceedings of the Controlled Release Society, pp. 919-920, 1997.
Chow, D. S., L. Gong, et al. “Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin.”Ann N Y Acad Sci 922:164-74, 2000.
Clements, M. K., C. B. Jones, et al. “Antiangiogenic potential of camptothecin and topotecan,”Cancer Chemother Pharmacol 44(5): 411-6, 1999.
Clements, M. K., S. Wasi, et al. “Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro.”Anticancer Drugs 7(8): 851-7, 1996.
Colbern, G. T., D. J. Dykes, et al. “Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.”Clin Cancer Res 4(12): 3077-82, Dec. 1998.
Daoud, S. S., M. I. Fetouh, et al. “Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts.”Anticancer Drugs 6(1): 83-93, 1995.
Dunton, C. J. “New options for the treatment of advanced ovarian cancer,”Semin Oncol 24(1 Suppl 5):S5-2-S5-11, Feb. 1997.
El-Kareh, A. W. and T. W. Secomb “Theoretical models for drug delivery to solid tumors.”Crit Rev Biomed Eng 25(6): 503-571, 1997.
Emerson, D. L. “Liposomal delivery of camptothecins,”Pharmaceutical Science and Technology Today 3(6): 205-209, Jun. 2000.
Emerson, D. L., N. Amirgahari, et al. “NX-211, a liposomal formulation of lurtotecan demonstrates enhanced pharmacokinetic and antitumor activity.”Proc Amer Assoc Cancer Res. 39: 278, Mar. 1998, Abstract #1897.
Emerson, D. L., R. Bendele, et al. “Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan,”Clin Cancer Res 6(7): 2903-12, Jul 2000.
Emerson, D., A. Gray, et al. “The topoisomerase I inhibitor, NX211 demonstrates significant in vivo activity against human acute myeloid leukemia (AML) engrafted in SCID mice.”Blood, 1999. Abstract #4223.
Erickson-Miller, C. L., R. D. May, et al. “Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro.”Cancer Chemother Pharmacol 39(5): 467-72, 1997.
Garcia-Carbonero, R. and J.G. Supko “Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.”Clin Cancer Res 8(3): 641-661, Mar. 2002.
Gelmon, K., H. Hirte, et al. “A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.”Invest New Drugs 2293): 263-75, 2004.
Giles, F. J., M. S. Tallman, et al. “Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.”Cancer 100(7): 1449-58, Apr. 2004.
Giles, F., M. Tallman, et al. “Phase I and pharmacokinetic study of OSI-211, a liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.”Blood, p. 2516, 2003. Abstract #4732.
Guo, W., A. Ahmad, et al. “Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38).”J Chromatogr B 791(1-2): 85-92, 2003.
Hatefi, A. and B. Amsden “Camptothecin delivery methods.”Pharm Res 19(10):1389-1399, Oct. 2002.
Khan, S., A. Ahmad, et al. “A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38).”Biomedical chromatography—BMC 17(8): 493-9, 2003.
Knight, V., E. S. Kleinerman, et al. “9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice.”Ann N Y Acad Sci 922: 151-63, 2000.
Knight, V., N. Koshkina, et al. “Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.”Trans Am Clin Climatol Assoc 111: 135-45, 2000.
Knight, V., N. V. Koshkina, et al. “Anticancer effect of 9-nitrocamptot
Madden Thomas D.
Semple Sean C.
Inex Pharmaceuticals Corporation
Lewis Amy
Low Christopher S. F.
Seed Intellectual Property Law Group PLLC
LandOfFree
Liposomal camptothecins and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomal camptothecins and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal camptothecins and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3701531